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Abstract
Background A novel endoscopic delivery system for
infrared coagulation therapy (IRC) has been designed
recently. IRC is a well-established treatment for symp-
tomatic internal hemorrhoids. Patients frequently undergo
lower endoscopy before hemorrhoid treatment to eliminate
other sources of bleeding. Current treatment options are
difficult to perform without an anal retractor, adequate
lighting, and specialized instruments. Endoscopic IRC is an
attractive alternative to standard IRC, because it can be
performed during the lower endoscopy.
Technique Endoscopic IRC utilizes infrared radiation
generated by a control box, which is applied to the tissue
through a flexible, fiber optic light guide (Precision
Endoscopic Infrared CoagulatorTM). The light guide is
placed through the colonoscope or flexible sigmoidoscope
in the same chamber as other endoscopic instruments.
Methods A retrospective review was performed using a
prospectively collected database. A standardized protocol
was utilized in all patients. Patients graded their symptoms
before and after therapy by using the visual analog symp-
tom severity scoring system (range, 0–10). These results
were analyzed by using the nonparametric Wilcoxon
signed-rank test. Exact P values were computed by using
the R function wilcox.exact.
Results A total of 55 patients underwent endoscopic IRC
for predominately grade II and grade III symptomatic
internal hemorrhoids (71 %). There were 22 (40 %) female
patients. Posttherapy results indicated a significant
improvement in global symptoms (pretreatment average
global score = 2.24 vs. posttreatment average global
score = 0.28; P \ 0.0001). There have been no adverse
events reported to date.
Conclusions Endoscopic IRC provides improved visibil-
ity and efficiency, allowing simultaneous treatment of
symptomatic internal hemorrhoids at the time of lower
endoscopy. Patients experienced significant improvement
in their symptoms after a single session of endoscopic IRC.
There are a variety of additional endoscopic IRC thera-
peutic utilities: endoscopic management of angiodysplasia,
inflammation, hemostasis, and NOTES applications.
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and Other Interventional Techniques 
Traditional surgical hemorrhoidectomy excises both the
internal and external hemorrhoid cushions and therefore is
associated with a great deal of pain during the postopera-
tive recovery period [1]. The significant pain associated
with this operation has led to a variety of nonsurgical
treatment options, which have been developed to treat
patients with symptoms primarily related to internal hem-
orrhoid disease. These nonsurgical treatment options
include rubber band ligation, infrared coagulation, bipolar
diathermy, direct-current electrotherapy, sclerotherapy, and
cryotherapy. All of these nonsurgical options cause fibro-
sis, scarring, shrinkage, and fixation of the internal hem-
orrhoid cushions and minimize symptoms of internal
hemorrhoid disease [2–4].
Patients with hemorrhoid disease are frequently
encouraged to undergo a colonoscopy before the initiation
of treatment for hemorrhoid disease to eliminate potential
neoplastic sources within the colon and rectum as a source
of the patient’s symptoms [5]. Currently, the nonsurgical
treatment options of internal hemorrhoid disease cannot be
done without the use of an anal retractor (anoscope),
dedicated lighting source, and specialized instruments
necessary for the nonsurgical treatment. In addition, non-
surgical treatment options are frequently performed at a
different time and location than the colonoscopy. This
leads to inefficiency for both time and expense for the
endoscopist, the endoscopy facility, and the patient.
Recently, an endoscopic infrared coagulator has been
developed which enables the endoscopist to treat the
internal hemorrhoid disease with infrared coagulation at
the same time as the lower endoscopy. The Precision
Endoscopic Infrared CoagulatorTM is FDA-approved for
the treatment of internal hemorrhoids grades I, II, and III
(Table 1). The technique of infrared coagulation utilizes
infrared radiation of 1–5 S pulse of energy applied onto the
internal hemorrhoid tissue through a light guide. The
infrared coagulator pulse of energy coagulates tissue pro-
tein and evaporates water from cells leading to coagulation,
obliteration, and eventual scaring and fixation of the
redundant hemorrhoid tissue.
Infrared coagulation (IRC) is a well-established treat-
ment option for symptomatic internal hemorrhoids. The
current standard infrared coagulator utilizes infrared radi-
ation generated by a tungsten-halogen lamp in a portable
control box, which is applied to the hemorrhoid tissue
through a solid quartz light guide at the tip of the infrared
coagulator (Infrared coagulator IRC2100TM, Redfield
Corporation, Rochelle Park, NJ). The endoscopic infrared
coagulator utilizes infrared radiation generated by a por-
table control box, which is applied to the hemorrhoid tissue
through a flexible, fiber optic light guide (Precision
Endoscopic Infrared CoagulatorTM, Precision Endoscopic
Technologies, Annapolis, MD). The light guide is placed
through the colonoscope or flexible sigmoidoscope in the
same accessory chamber as other endoscopic instruments
(biopsy forceps, snare cautery, endocatch bags, etc.). The
endoscopic infrared coagulator allows for direct endo-
scopic visualization of the procedure. The improved visi-
bility with the endoscopic application compared with the
anal retractor application of infrared coagulation is an
attractive feature of the new medical device.
Methods
Study design
A retrospective review was performed by using a pro-
spectively collected database registry. Patient selection
included age 18–80 years, rectal bleeding attributed to
internal hemorrhoids on at least a weekly basis for
3 months or more, and no previous infrared therapy for
internal hemorrhoids. Using a standardized protocol, each
patient then underwent a thorough history and physical
examination. Anoscopy, sigmoidoscopy, or colonoscopy
also was performed to eliminate other sources of bleeding.
Demographic data were collected exclusive of any patient-
identifying information to ensure the confidentiality of the
data collection process. Information pertaining to the
hemorrhoid location, grade, and patient symptoms also was
collected.
The patient’s hemorrhoids were graded by using the
Banov scale of grade I–IV (Table 1) [6]. Patients were
excluded from participation if they had a history of cancer
not in remission for 5 years or more, prior hemorrhoid
treatment in past 12 months, history of pelvic radiation,
personal history of inflammatory bowel disease, anticoag-
ulation therapy, concurrent anal fistula or fissure, advanced
renal, cardiac disease, pulmonary disease, artificial
mechanical heart valve or shunt, and inability to tolerate
endoscopy with sedation. The patient’s performed self-
symptom severity assessments before and after therapy.
The posttherapy symptom severity evaluation was per-
formed 6 weeks after the initial treatment. Self-symptom
severity assessment included a six-point visual analog scale
Table 1 Banov internal hemorrhoid grading system [6]
Grade Description
I Bleeding, no prolapsed
II Prolapse with spontaneous reduction, ±bleeding
III Prolapse that requires manual reduction, ±bleeding
IV Prolapse that cannot be reduced, usually both internal and
external hemorrhoid components confluent from external




rating the severity of bleeding, prolapse, pain, itching,
burning, and soiling on a scale of 0–10. A global score was
constructed by averaging these six components.
The treatment of internal hemorrhoids with the endo-
scopic infrared coagulator (Precision Endoscopic Infrared
CoagulatorTM) was performed either in an office setting or
outpatient surgical setting. The treatment was performed in
conjunction with a flexible sigmoidoscopy or colonoscopy.
Subjects had the option to receive sedation during the
procedure at their request or at the discretion of the treating
physician. The treatment was performed in accordance
with the methodology, and procedure sections of a stan-
dardized protocol were provided to each participating
physician. The six participating physicians included spe-
cialists in gastroenterology, general surgery, and colorectal
surgery experienced in diagnostic and therapeutic endos-
copy, standard infrared coagulation therapy, and endo-
scopic and anoscopic-guided rubber band ligation.
Collection, analysis, and reporting of data from the various
participating physician sites were coordinated by Investi-
gative Clinical Research, Annapolis, Maryland. The results
were analyzed for statistical significance in each symptom
using the nonparametric Wilcoxon signed-rank test. Exact
P values were computed by using the R function wil-
cox.exact by D.O. Scharfstein, professor of biostatistics,
ScD (Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD) [7].
Emerging technology device
The PRECISIONTM endoscopic infrared coagulator device
consists of two units:
1. A control unit that houses a source of infrared energy
and control circuitry, which is plugged into a standard
AC electrical outlet, and
2. A single-use disposable MAXi-guideTM flexible fiber
optic light guide whose proximal end is connected to
the control unit by a quick-connect threaded handle,
and whose distal tip is inserted into the accessory
channel of a colonoscope, flexible sigmoidoscope, or
other flexible endoscope.
The current configuration of the single-use disposable
flexible light guide is 3.2 mm in outer diameter, and the
overall length of this flexible light guide is 300 cm. When
in use, visible light and infrared energy enter the proximal
end of the fiber optic and are passed through its entire
length to the distal tip. As the distal tip is placed in contact
with tissue, infrared energy is transferred to the tissue,
rapidly increasing the temperature and coagulating the
tissue. The PRECISIONTM endoscopic infrared coagulator
device was cleared to market in the United States by the
Food and Drug Administration in June 2009 through the
510(k) procedure (K083275). This device also carries the
CE Mark (CE 542048) and US Patent 7,977,658.
Description of the procedure
After explanation of the procedure and obtaining informed
consent, the patients were placed in the left-lateral decu-
bitus position. Visual and digital inspection of the anus and
rectum were performed, and any abnormal findings were
noted. The patient’s had the option to receive sedation at
his or her request. Either flexible colonoscopy or sig-
moidoscopy was performed with an instrument having at
least a 3.7 mm instrument channel. After evaluation of the
bowel, the instrument was retroflexed, and the anorectal
junction was inspected carefully. The internal hemorrhoid
area was evaluated, and any bleeding, prolapse, or other
abnormal findings were noted.
The endoscope was straightened, and the PRE-
CISIONTM Endoscopic Infrared Coagulator single-use
flexible fiber optic probe inserted into the endoscope
through the biopsy cap. Before insertion, it was gently
lubricated on its entire length. The flexible fiber optic probe
was inserted using gentle short strokes, taking care not to
kink the fiber optic cables upon insertion. The fiber optic
probe was advanced until it protruded 1–2 cm from the tip
of the scope. The endoscope was then retroflexed in the
rectum, and the hemorrhoid columns were identified.
Endoscopic infrared coagulation treatment was applied by
gently opposing the tip of the probe to the tissue just above
the engorged internal hemorrhoid tissue column. The probe
was held in place for up to 3–5 S. The probe was then
moved to an adjacent location in an overlapping semilunar
‘‘W’’ fashion (Fig. 1). Treatment was performed on one to
three internal hemorrhoid quadrants at the discretion of the
endoscopist.
Follow-up
Follow-up evaluation was performed at approximately
6 weeks by anoscopy or consultation. A second session
was allowed and performed approximately 90 days after
the initial therapy if residual symptoms or tissue required
additional therapy. The patients were given instructions to
maintain soft stools for several days after therapy with
stool softeners and/or appropriate fiber intake.
Results
Fifty-five patients underwent endoscopic infrared coagu-
lation therapy using the PRECISIONTM Endoscopic
Infrared Coagulator. The grade of internal hemorrhoids
was predominately grade II and III (Table 2). There were
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22 (40 %) female patients (Table 3). Pretreatment bowel
habits and symptoms associated with internal hemorrhoids
are displayed in Table 4. No intention-to-treat analysis was
performed, because only three patients were excluded. Two
patients developed psychiatric disturbances that led to an
inaccurate reporting of symptoms. The third patient was
excluded due to a diagnosis of hepatitis C and cirrhosis
after initial evaluation.
Posttherapy results indicated an average improvement of
87.6 % in global symptoms attributed to internal hemor-
rhoids (pretreatment average global score = 2.24 vs.
posttreatment average global score = 0.28; P \ 0.0001;
Table 5). Fifty-three patients received a single treatment,
and two patients underwent a second treatment session. In
49 patients (89 %), the posttreatment severity scores were
the same or lower than the pretreatment severity scores on
all six components. There were six patients with an
increase in at least one component. In these six patients, the
overall global scores all decreased; one patient experienced
an increase in bleeding (from 1.2 to 2.2); two patients
experienced an increase in prolapse (0.0–3.3 and 0.0–2.0),
one patient experienced an increase in pain (0.0–0.7), two
patients experienced an increase in itching (0.0–2.9 and
1.7–1.9), none experienced an increase in burning, and one
patient experienced an increase in soiling (0.0–0.7). There
have been no adverse events reported to date.
Discussion
Symptomatic internal hemorrhoid engorgement is a com-
mon human condition. Symptoms may include bleeding,
itching, burning, tissue prolapse, and fecal seepage. Inter-
nal hemorrhoids that are unresponsive to dietary modifi-
cation and topical and suppository agents may be treated
with rubber band ligation, coagulation therapy (infrared
beam, electric current, CO2 laser, ultrasonic energy, cryo-
therapy), or sclerosing agents. These treatment options
require the use of an anal retractor, adequate lighting, and
specialized instruments. These requirements often restrict
the utilization of these treatment options at the time of
screening colonoscopy for rectal bleeding. These limita-
tions delay treatment of the patient’s symptoms. In
Fig. 1 Overlapping ‘‘W’’:
semi-lunar spot endoscopic IRC
technique. IRC infrared
coagulation
Table 2 Internal hemorrhoids grade and location
Internal hemorrhoid data
Grade I Grade II Grade III Grade IV Not recorded
Internal hemorrhoids (# patients) 6 19 20 3 7
Left lateral Right anterior Right posterior Not recorded
Location of hemorrhoids (# incidence) 33 22 19 18
Table 3 Patient demographics
No. of patients 55
Median age (year) 46 (16–77)
Female 40 % (22)
History of childbirth 32 % (18)
History of episiotomy 16 % (9)
Family history colorectal cancer 16 % (9)
Prior colonoscopy 78 % (43)
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addition, this is an inefficient use of time and resources
for the patient, physician, and potentially the health care
system.
The endoscopic infrared coagulator is a novel and attrac-
tive alternative to standard infrared coagulation, because it can
be performed at the same time as the lower endoscopy through
the accessory channel of the endoscope. Endoscopic delivery
of infrared coagulation offers improved lighting and visuali-
zation compared with current anoscopic guided therapy for
symptomatic internal hemorrhoids. After a single session of
endoscopic infrared coagulation, patients in this study expe-
rienced a statistically significant improvement of their
symptoms related to internal hemorrhoids.
The authors readily acknowledge that there are several
limitations to this preliminary study. This study utilizes the
patients as their own internal controls by comparing patient
self-scoring of the severity of symptoms attributed to
hemorrhoid disease before and after therapy. The study did
not utilize ultrasound to guide the site of infrared coagu-
lation application or monitor reduction in venous blood
flow after the procedure. Finally, the study did not compare
the efficacy of the new technology with the current
standard of care delivery mode for infrared coagulation
therapy for internal hemorrhoids.
Despite these limitations, the improved visibility of the
Precision Endoscopic Infrared CoagulatorTM without the
need for anal retractors and specialized light source is an
attractive feature for the treatment of symptomatic internal
hemorrhoids. The use of the endoscopic infrared coagula-
tion allows for simultaneous diagnostic and therapeutic
endoscopy for rectal bleeding. If symptoms persist or recur,
additional treatments can be performed with endoscopic
infrared coagulation therapy or other nonoperative tech-
niques as previously described at the discretion of the
physician and patient.
Future clinical trials are being developed to evaluate
further the effectiveness of the device for obtaining
hemostasis in the setting of angiodysplasia, radiation
proctitis, and endoscopic biopsy/polypectomy. Endoscopic
ablation of esophageal, anal, and rectal dysplasia is another
field of potential therapeutic utility. In addition, a variety of
applications are undergoing investigation in the rapidly
evolving arena of natural orifice transluminal endoscopic
surgery (NOTES).
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Table 4 Bowel habits and
hemorrhoid symptoms
BM bowel movement
No. of years hemorrhoids present 0–10 years [10 years Unknown
62 % (34) 22 % (12) 16 % (9)
Blood in stool Frequently Occasionally Never
24 % (13) 58 % (32) 18 % (10)
Hemorrhoids protrude 31 % (17) 29 % (16) 34 % (19)
Straining with BM 29 % (16) 49 % (27) 22 % (12)
Constipation 18 % (10) 60 % (33) 22 % (12)
Hard and firm stools 30 % (17) 56 % (31) 12 % (7)
Feel lump in rectum 18 % (10) 24 % (13) 55 % (30)
Pain with BM 18 % (10) 30 % (17) 51 % (28)
Drainage around rectum 3 % (2) 24 % (13) 73 % (40)
Soil underwear 5 % (3) 27 % (15) 65 % (36)
Laxative use 7 % (4) 29 % (16) 68 % (34)
Fiber supplement use 22 % (12) 34 % (19) 38 % (21)






Bleeding 3.81 (3.1) 0.37 (0) \0.0001
Prolapse 1.47 (0) 0.39 (0) 0.0005
Pain 2.37 (1.9) 0.16 (0) \0.0001
Itching 2.29 (1.5) 0.36 (0) \0.0001
Burning 2.33 (1.5) 0.14 (0) \0.0001
Soiling 1.16 (0) 0.23 (0) 0.0001
* Exact P values computed using the R function wilcox.exact
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